Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AP-001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : PACE
Deal Size : $1.2 million
Deal Type : Funding
ArrePath Secures £1M PACE Grant to Advance Antibiotics for Drug-Resistant Infections
Details : The proceeds will be used to develop a new class of antibiotics designed to address multidrug-resistant (MDR) infections, including AP-001 for the treatment of complicated urinary tract infections.
Brand Name : AP-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 19, 2024
Lead Product(s) : AP-001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : PACE
Deal Size : $1.2 million
Deal Type : Funding
Lead Product(s) : Anti-infective Therapeutic
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery Platform
Sponsor : Venture Fund
Deal Size : $20.0 million
Deal Type : Financing
Details : The funding will enable the advancement of initial leads and expansion of discovery efforts, as well as the enhancement of imaging platform and the application of machine learning in the discovery of new drugs to address critical global health challenges...
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
March 03, 2022
Lead Product(s) : Anti-infective Therapeutic
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery Platform
Sponsor : Venture Fund
Deal Size : $20.0 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?